ISIS Pharmaceuticals, Inc. (Public, NASDAQ:ISIS)

This is more of a momentum short play than recent ones where I have attempted to identify movers before they turn into momemtum plays. I don't really trust little biotech stocks like this one because when I read their descriptions (see below) all I get from them is that is complicated science which is way above my head. What I like here is the stock is holding up very well after a recent rally (shorts bidding before they have to chase?) and there are a lot of recent shorts in the stock who may look to mininmize their losses.

If you are still holding SIFY, you are greedier than I am. I will look to repurchase at some point over the next several days.




Isis Pharmaceuticals, Inc. is a biopharmaceutical company exploiting ribonucleic acid (RNA)-based drug discovery technologies to create a class of drugs to treat important diseases. The Company, with its primary technology, antisense, creates inhibitors, called oligonucleotides, designed to hybridize, with a high degree of specificity to their RNA target and modulate the production of specific proteins associated with disease. Separately, within the Company’s Ibis Biosciences, Inc. subsidiary, Isis Pharmaceuticals, Inc. has developed a biosensor system, called the Ibis T5000 Biosensor System, which can simultaneously identify from a sample a range of infectious organisms without needing to know beforehand what might be present in the sample. The Company is commercializing the Ibis T5000 Biosensor System for use in biodefense, forensics, epidemiological surveillance, infectious disease research, hospital-associated infection control.